Skip To Main Content
David Bates on Muck Rack

David Bates

Huntsville
As seen in: Medium, Color Research & Application, Nature, Wiley Online Library, Canadian Broadcasting Corporation (CBC), CBXL-FM (High Level, AB), PLOS Medicine, BMJ Quality & Safety, Harvard Business Review, MDPI and
Married to the love of my life Patricia and father of Nik and Megan and G-Pa of Kristabelle Rose. Member of the Hellfighter Motorcycle Ministry.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with David

Contact David, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Autoimmune Disease Risk With GLP‐1RA, DPP‐4i, and SGLT2i Treatment in Patients With Diabetes

|
By Arjun Yash Mahajan, David Bates, Alessandro Doria, Dinah Foer, Avery LaChance, Jeffrey A Sparks
| Wiley Online Library Verified
Open in Who Shared Issue with article?

Autoimmune Disease Risk With GLP-1RA, DPP-4i, and SGLT2i Treatment in Patients With Diabetes

|
By Immunity Brigham, Arjun Mahajan MS, David W. Bates MD, Arjun Yash Mahajan, David Bates, Alessandro Doria, Dinah Foer, Avery LaChance, Jeffrey A Sparks
| Wiley Online Library Verified
INTRODUCTION Dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like peptide-1 receptor agonists (GLP-1RA), and sodium-glucose cotransporter-2 inhibitors (SGLT2i) have become mainstays of therapy for type 2 diabetes mellitus, together reaching over 1 in 10 adults in the United States.1, 2 Although extensive cardiorenal outcome data exist for GLP-1RA, SGLT2i, and DPP-4i, the immunologic safety of these agents remains relatively uncertain; current evidence is often limited to small or...
Open in Who Shared Issue with article?

Hematologic and solid-organ malignancy risk in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis - Communications Medicine

|
By David Bates
| Nature Verified
Abstract Antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) is a rare autoimmune disease characterized by small- and medium-vessel inflammation. Although chronic immune dysregulation and cytotoxic therapy exposure have been hypothesized to increase malignancy risk, large-scale, real-world evidence quantifying these risks has been limited.
Open in Who Shared Issue with article?
See all 92 licensed articles (93 Total)